Article

Exploring Viral, Environmental, and Immunologic Bases for Multiple Sclerosis

Neurology Reviews. 2008 November;16(11):10

 

References


—Wayne Kuznar

Pages

Recommended Reading

No PML Seen With Natalizumab Since Summer '06
MDedge Neurology
Steroid Added to Interferon-β Cuts MS Relapses : The relapse rate in patients receiving the combination was about a third of that seen in placebo patients.
MDedge Neurology
Data Watch: Obstacles to Insurance Coverage of Specific Therapies for Multiple Sclerosis
MDedge Neurology
Red Flags in Neurologic Examinations Point to MS
MDedge Neurology
Clinical Trial Digest: Findings from Recently Published Randomized Controlled Trials
MDedge Neurology
Can Neuropsychiatric Symptoms Be Predicted in Patients With MS and Cognitive Impairment?
MDedge Neurology
Reuters Health Information
MDedge Neurology
Challenging the Status Quo in Understanding MS
MDedge Neurology
Do Current Outcome Measures Underestimate the Impact of Multiple Sclerosis?
MDedge Neurology
Reuters Health Information: July 2008
MDedge Neurology